December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Yüksel Ürün: KEYNOTE-412 trial shows pembrolizumab + chemoradiotherapy doesn’t significantly improve event-free survival in unselected advanced head and neck squamous cell carcinoma vs placebo
Apr 2, 2024, 21:45

Yüksel Ürün: KEYNOTE-412 trial shows pembrolizumab + chemoradiotherapy doesn’t significantly improve event-free survival in unselected advanced head and neck squamous cell carcinoma vs placebo

Yüksel Ürün, Medical Oncologist at Ankara University, shared a post on X/Twitter:

“KEYNOTE-412 trial shows pembrolizumab + chemoradiotherapy doesn’t significantly improve event-free survival in unselected advanced head and neck squamous cell carcinoma vs placebo. More targeted approaches needed to enhance outcomes.”

Read further.
Source: Yüksel Ürün/X